PEČINKA, Lukáš, Lukáš MORÁŇ, Monika VLACHOVÁ, Adam BŘEZINA, Petra KOVAČOVICOVÁ, Martina MARCHETTI-DESCHMANN, Sabina ŠEVČÍKOVÁ, Josef HAVEL, Aleš HAMPL and Petr VAŇHARA. Biostatistic and machine learning in MALDI mass spectrometry research. In XXII. Interdisciplinary meeting of young life scientists. 2023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Biostatistic and machine learning in MALDI mass spectrometry research
Authors PEČINKA, Lukáš (203 Czech Republic, belonging to the institution), Lukáš MORÁŇ (203 Czech Republic, belonging to the institution), Monika VLACHOVÁ (203 Czech Republic, belonging to the institution), Adam BŘEZINA (203 Czech Republic, belonging to the institution), Petra KOVAČOVICOVÁ (703 Slovakia, belonging to the institution), Martina MARCHETTI-DESCHMANN (40 Austria), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Josef HAVEL (203 Czech Republic, belonging to the institution), Aleš HAMPL (203 Czech Republic, belonging to the institution) and Petr VAŇHARA (203 Czech Republic, guarantor, belonging to the institution).
Edition XXII. Interdisciplinary meeting of young life scientists, 2023.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30400 3.4 Medical biotechnology
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/23:00132354
Organization unit Faculty of Medicine
Keywords in English mass spectrometry; biotyping; machine learning; tissue engineering
Changed by Changed by: doc. RNDr. Petr Vaňhara, Ph.D., učo 43385. Changed: 14/12/2023 13:12.
Abstract
With increasing demands on precise analyses of biological samples in complex biological matrices, there is also a need to develop and optimize mass spectrometric (MS) methods. MS analysis of whole cells, plasma samples, and other biological materials is of great importance for monitoring and elucidating biological processes in the organism and provides important information regarding organism pheno/genotype. In two topics presented herein, different techniques for whole cell samples and peripheral blood plasma will be presented. The whole cell MALDI TOF MS is already used in clinical microbiology and diagnostics. In recent years it has been introduced also to cell biology, immunology, and cancer biology. The first project focuses on classifying ovarian cancer cells with different percentages of cell populations with a knockout of a single gene (TUSC3). Different cell types (4 in total) from different organisms (human and mouse) were introduced to MS analysis. MS method was combined with multivariate statistical and machine learning algorithms (PLS-DA, ANN, and RF for example) using an R programming language. Data obtained from MS were analysed via an in-house developed R-script. In total 5 optimized classifiers based on different algorithms were established and compared for 175 mass spectra divided into 5 groups. PLS-DA was determined as a model with the best performance with 100% accuracy (95% confidence interval, Cl = 94.7-100%) for the test data. The method described above was further used for other studies; to follow the differentiation process of hESCs to ELEPs for example. We visualized the full differentiation trajectory based on spectral data only and revealed also some phenotypic abnormalities linked to passage number, and by proxy aneuploidy status of hESCs. The second project is dealing with the development method for the analysis of human plasma samples using MALDI TOF MS. This project aims to discriminate multiple myeloma (MM) patients and patients with similar diseases like plasma cell leukemia (PCL) and extramedullary multiple myeloma (EMD). The two steps protein extraction protocol was developed for the classification of MM, PCL, and EMD patients. Intensity across the whole m/z range increased approx. 50 times when extraction protocol was used (compare to dilute direct plasma samples). The accuracy of classification models using ML algorithms (RF, PLS-DA, and ANN) was 80-90% for the training dataset and 80-85% for the test dataset. These findings may help accelerate the integration of MALDI MS into a clinical application as the diagnosis of MM, PCL, and EMD is rather inaccurate nowadays.
Links
LX22NPO5102, research and development projectName: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)
Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES
MUNI/A/1298/2022, interní kód MUName: Základní a aplikovaný výzkum a vývoj metod chemické a fyzikálně chemické analýzy pro studium přírody a pokročilé technologie
Investor: Masaryk University, Basic and applied research and development of chemical and physicochemical analytical methods for the study of nature and advanced technology
MUNI/A/1370/2022, interní kód MUName: Patofyziologie vybraných komplexních nemocí od molekulární do systémovou úroveň
Investor: Masaryk University, Pathophysiology of selected complex diseases from molecular to systemic level
MUNI/11/ACC/3/2022, interní kód MUName: Bioanalytical quality control of cGMP/ATMP-grade stem cells and progenitors
Investor: Masaryk University, Accelerate
NU21-03-00076, research and development projectName: Využití MALDI-TOF hmotnostní spektrometrie pro identifikaci molekulárních vzorců u relabovaných pacientů s mnohočetným myelomem
Investor: Ministry of Health of the CR, Subprogram 1 - standard
PrintDisplayed: 17/5/2024 13:31